TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway

Sur-Erdem, İlknur; Muslu, Kerem; Pınarbası, Nareg; Altunbek, Mine; Seker-Polat, Fidan; Cingöz, Ahmet; Aydın, Serdar; Kahraman, Mehmet; Çulha, Mustafa; Solaroğlu, İhsan; Bagcı-Önder, Tugba

doi:10.1080/01616412.2020.1796378

Cited by 14 publications

(12 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TRAIL-iron oxide NPs also blocked tumor growth and prolonged the survival rate of xenografts compared with control and TRAIL monotherapy ( 32 ). As well, TRAIL delivery using polyethyleneimine (PEI)-poly[(1,6-hexanediol)-diacrylate-β-5-hydroxyamylamine] (PBAE) in TNBC ( 176 ), silver NPs (AgNPs) in glioblastoma ( 177 ), TPGS-b-(PCL-ran-PGA)/PEI NPs in cervical cancer ( 178 ), neutrophil membrane (NM)-based NPs in various cancers ( 179 ), and artificial lipid NPs in colon cancer ( 180 ), leukemia ( 181 ), sarcoma ( 182 ), and also TNBC ( 30 ) has been suggested as authentically and operational therapeutic approach.…”

Section: Trail Delivery Using Npsmentioning

confidence: 99%

RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

et al. 2021

View full text Add to dashboard Cite

The immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted rapidly evolving attention as a cancer treatment modality because of its competence to selectively eliminate tumor cells without instigating toxicity in vivo. TRAIL has revealed encouraging promise in preclinical reports in animal models as a cancer treatment option; however, the foremost constraint of the TRAIL therapy is the advancement of TRAIL resistance through a myriad of mechanisms in tumor cells. Investigations have documented that improvement of the expression of anti-apoptotic proteins and survival or proliferation involved signaling pathways concurrently suppressing the expression of pro-apoptotic proteins along with down-regulation of expression of TRAILR1 and TRAILR2, also known as death receptor 4 and 5 (DR4/5) are reliable for tumor cells resistance to TRAIL. Therefore, it seems that the development of a therapeutic approach for overcoming TRAIL resistance is of paramount importance. Studies currently have shown that combined treatment with anti-tumor agents, ranging from synthetic agents to natural products, and TRAIL could result in induction of apoptosis in TRAIL-resistant cells. Also, human mesenchymal stem/stromal cells (MSCs) engineered to generate and deliver TRAIL can provide both targeted and continued delivery of this apoptosis-inducing cytokine. Similarly, nanoparticle (NPs)-based TRAIL delivery offers novel platforms to defeat barricades to TRAIL therapeutic delivery. In the current review, we will focus on underlying mechanisms contributed to inducing resistance to TRAIL in tumor cells, and also discuss recent findings concerning the therapeutic efficacy of combined treatment of TRAIL with other antitumor compounds, and also TRAIL-delivery using human MSCs and NPs to overcome tumor cells resistance to TRAIL.

show abstract

Section: Trail Delivery Using Npsmentioning

confidence: 99%

RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Experiments with silver-cysteine nanoparticles and TRAIL-conjugated silver nanoparticles coated with PEG (AgCTP NPs) showed that AgCTPNPs exhibited apoptotic effects in HT-29 colon cancer cell line in vitro with substantial differences in the expression levels of Bax, Bcl-2, and cleaved PARP protein [110] . TRAILconjugated (TRAIL-AgNPs) induced death receptor activation in T98 G TRAIL-Resistant (TR) glioblastoma cells.…”

Section: Silver Nanoparticlesmentioning

confidence: 99%

Nano-TRAIL: a promising path to cancer therapy

Gampa¹

2023

Cancer Drug Resist

View full text Add to dashboard Cite

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, also called apo-2 ligand (TRAIL/Apo-2L), is a cytokine that triggers apoptosis by binding to TRAIL-R1 (DR4) and TRAIL-R2 (DR5) death receptors. Apoptosis occurs through either the extrinsic or intrinsic pathway. The administration of recombinant human TRAIL (rhTRAIL) or TRAIL-receptor (TRAIL-R) agonists promotes apoptosis preferentially in cancerous cells over normal cells in vitro; this phenomenon has also been observed in clinical studies. The limited efficacy of rhTRAIL in clinical trials could be attributed to drug resistance, short half-life, targeted delivery issues, and off-target toxicities. Nanoparticles are excellent drug and gene delivery systems characterized by improved permeability and retention, increased stability and biocompatibility, and precision targeting. In this review, we discuss resistance mechanisms to TRAIL and methods to overcome TRAIL resistance by using nanoparticle-based formulations developed for the delivery of TRAIL peptides, TRAIL-R agonists, and TRAIL genes to cancer cells. We also discuss combinatorial approaches of chemotherapeutic drugs with TRAIL. These studies demonstrate TRAIL’s potential as an anticancer agent.

show abstract

“…Since oxidative stress has been shown to sensitize some cancer cells to TRAIL, numerous studies have demonstrated that co-delivering TRAIL with metal NPs could achieve the same effect [ 184 , 277 ]. The challenge in using metal NPs is their limited flexibility for oriented conjugation of proteins, such as TRAIL and accordingly, studies to date have predominantly relied on electrostatic- and amide-based conjugation on iron and silver NPs ( Figure 3 ) [ 278 , 279 ].…”

Section: Trail Formulations To Mimic Membrane-bound Trailmentioning

confidence: 99%

TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems

Zeinabad

Szegezdi

2022

Cancers

View full text Add to dashboard Cite

The death ligand tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF cytokine superfamily, has long been recognized for its potential as a cancer therapeutic due to its low toxicity against normal cells. However, its translation into a therapeutic molecule has not been successful to date, due to its short in vivo half-life associated with insufficient tumor accumulation and resistance of tumor cells to TRAIL-induced killing. Nanotechnology has the capacity to offer solutions to these limitations. This review provides a perspective and a critical assessment of the most promising approaches to realize TRAIL’s potential as an anticancer therapeutic, including the development of fusion constructs, encapsulation, nanoparticle functionalization and tumor-targeting, and discusses the current challenges and future perspectives.

show abstract

TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway

Cited by 14 publications

References 41 publications

RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

Nano-TRAIL: a promising path to cancer therapy

TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems

Contact Info

Product

Resources

About